# Module 7: Competency Assessment

!!! abstract "Time: 30 minutes"

    Self-assessment of benefit-risk knowledge, skills, and capability development planning.

## Learning Objectives

After completing this module, you will be able to:

- [x] Assess your current B-R competency level
- [x] Identify strengths and development areas
- [x] Create a personalized capability development plan
- [x] Track progress over time

## Materials

| File | Description |
|------|-------------|
| `BR_Self_Assessment_Quiz.docx` | Knowledge check and development planning |

---

## Assessment Overview

This self-assessment covers the five core competency domains of benefit-risk assessment. Answer honestlyâ€”this is for your development, not a test with right or wrong answers.

!!! tip "How to Use This Assessment"

    1. **Complete all sections** â€” Don't skip questions
    2. **Be honest** â€” Accurate self-assessment enables targeted development
    3. **Note evidence** â€” What experiences support your rating?
    4. **Identify gaps** â€” Where do you need most development?
    5. **Create a plan** â€” Turn insights into action

---

## Part 1: Knowledge Assessment

### Domain 1: Framework & Methodology

Rate your knowledge (1 = Novice, 5 = Expert):

| Topic | 1 | 2 | 3 | 4 | 5 |
|-------|---|---|---|---|---|
| CIOMS WG XII recommendations | â˜ | â˜ | â˜ | â˜ | â˜ |
| Structured Benefit-Risk Framework (SBRF) steps | â˜ | â˜ | â˜ | â˜ | â˜ |
| Regulatory expectations (FDA, EMA, ICH) | â˜ | â˜ | â˜ | â˜ | â˜ |
| BRAD structure and purpose | â˜ | â˜ | â˜ | â˜ | â˜ |
| Lifecycle B-R approach | â˜ | â˜ | â˜ | â˜ | â˜ |

**Self-reflection:** *Which framework element do you use most frequently in your work?*

---

### Domain 2: Quantitative Methods

Rate your knowledge (1 = Novice, 5 = Expert):

| Topic | 1 | 2 | 3 | 4 | 5 |
|-------|---|---|---|---|---|
| Effects tables construction | â˜ | â˜ | â˜ | â˜ | â˜ |
| DOOR methodology | â˜ | â˜ | â˜ | â˜ | â˜ |
| MCDA principles and weighting | â˜ | â˜ | â˜ | â˜ | â˜ |
| NNT/NNH calculations | â˜ | â˜ | â˜ | â˜ | â˜ |
| Sensitivity analysis approaches | â˜ | â˜ | â˜ | â˜ | â˜ |
| Statistical interpretation (CI, RR, HR) | â˜ | â˜ | â˜ | â˜ | â˜ |

**Self-reflection:** *Which quantitative method would you feel confident presenting to a regulatory body?*

---

### Domain 3: Visualization & Communication

Rate your knowledge (1 = Novice, 5 = Expert):

| Topic | 1 | 2 | 3 | 4 | 5 |
|-------|---|---|---|---|---|
| Forest plot interpretation and creation | â˜ | â˜ | â˜ | â˜ | â˜ |
| Tornado diagram application | â˜ | â˜ | â˜ | â˜ | â˜ |
| B-R heatmap design | â˜ | â˜ | â˜ | â˜ | â˜ |
| Tailoring communication to audience | â˜ | â˜ | â˜ | â˜ | â˜ |
| Value tree construction | â˜ | â˜ | â˜ | â˜ | â˜ |

**Self-reflection:** *How confident are you explaining B-R data to a non-technical audience?*

---

### Domain 4: Stakeholder Integration

Rate your knowledge (1 = Novice, 5 = Expert):

| Topic | 1 | 2 | 3 | 4 | 5 |
|-------|---|---|---|---|---|
| Patient preference study methods | â˜ | â˜ | â˜ | â˜ | â˜ |
| Incorporating patient perspectives | â˜ | â˜ | â˜ | â˜ | â˜ |
| HCP engagement in B-R | â˜ | â˜ | â˜ | â˜ | â˜ |
| Cross-functional collaboration | â˜ | â˜ | â˜ | â˜ | â˜ |
| Regulatory interaction strategies | â˜ | â˜ | â˜ | â˜ | â˜ |

**Self-reflection:** *When did you last directly engage patients or patient advocates in B-R discussions?*

---

### Domain 5: Risk Management

Rate your knowledge (1 = Novice, 5 = Expert):

| Topic | 1 | 2 | 3 | 4 | 5 |
|-------|---|---|---|---|---|
| Risk categorization (identified, potential, missing) | â˜ | â˜ | â˜ | â˜ | â˜ |
| RMM selection and design | â˜ | â˜ | â˜ | â˜ | â˜ |
| RMM effectiveness evaluation | â˜ | â˜ | â˜ | â˜ | â˜ |
| REMS/aRMM requirements | â˜ | â˜ | â˜ | â˜ | â˜ |
| Post-marketing surveillance integration | â˜ | â˜ | â˜ | â˜ | â˜ |

**Self-reflection:** *Can you describe an RMM you helped design or evaluate?*

---

## Part 2: Skills Assessment

### Practical Application

For each skill, rate your proficiency based on actual experience:

| Skill | Never Done | Done Once | Done Several Times | Do Regularly | Could Teach Others |
|-------|------------|-----------|-------------------|--------------|-------------------|
| Led/contributed to BRAD development | â˜ | â˜ | â˜ | â˜ | â˜ |
| Constructed an effects table | â˜ | â˜ | â˜ | â˜ | â˜ |
| Performed DOOR or MCDA analysis | â˜ | â˜ | â˜ | â˜ | â˜ |
| Presented B-R to regulators | â˜ | â˜ | â˜ | â˜ | â˜ |
| Designed patient preference research | â˜ | â˜ | â˜ | â˜ | â˜ |
| Developed RMM materials | â˜ | â˜ | â˜ | â˜ | â˜ |
| Created B-R visualizations | â˜ | â˜ | â˜ | â˜ | â˜ |
| Conducted sensitivity analysis | â˜ | â˜ | â˜ | â˜ | â˜ |

---

## Part 3: Module Quick Checks

Test your understanding with rapid-fire questions for each module:

### Module 1: Leadership Briefing

??? question "What are the five CIOMS WG XII recommendations?"

    1. **Adopt a structured approach** â€” Use SBRF or equivalent framework
    2. **Consider a lifecycle approach** â€” B-R evolves from development through post-marketing
    3. **Customize to context** â€” Adapt methods to the specific decision
    4. **Engage stakeholders** â€” Include patient and HCP perspectives
    5. **Document transparently** â€” Capture methodology, assumptions, and limitations

    ðŸ“– *Review: [Module 1](01-leadership-briefing.md)*

### Module 2: Foundation

??? question "What are the six steps of the Structured Benefit-Risk Framework (SBRF)?"

    1. **Decision Context** â€” What decision? For whom? Compared to what?
    2. **Identify Outcomes** â€” Benefits and risks that matter
    3. **Data Sources** â€” Evidence quality and availability
    4. **Outcome Importance** â€” Relative importance of each outcome
    5. **Outcome Probability** â€” How likely is each outcome?
    6. **Integrate B-R** â€” Combine into overall assessment

    ðŸ“– *Review: [Module 2](02-foundation.md)*

### Module 3: Decision Support

??? question "When should you use DOOR vs. MCDA?"

    **Use DOOR when:**

    - Composite endpoints with natural hierarchy (e.g., death > hospitalization > symptoms)
    - Patient values relatively uniform
    - Want to avoid arbitrary numerical weights

    **Use MCDA when:**

    - Multiple stakeholder groups with different values
    - Need explicit, transparent weighting
    - Trade-offs between qualitatively different outcomes

    ðŸ“– *Review: [Module 3](03-decision-support.md)*

### Module 4: Assessment Templates

??? question "What are the three core B-R templates and their purposes?"

    | Template | Purpose |
    |----------|---------|
    | **BRAD** | Benefit-Risk Action Document â€” Living document for regulatory decisions |
    | **Effects Table** | Structured data presentation â€” Quantifies benefits and risks |
    | **Value Tree** | Hierarchical outcome map â€” Identifies all relevant outcomes |

    ðŸ“– *Review: [Module 4](04-assessment-templates.md)*

### Module 5: Visualization Tools

??? question "Match the visualization to the purpose:"

    | Visualization | Best For |
    |---------------|----------|
    | **Forest Plot** | Relative measures (RR, OR, HR) with confidence intervals |
    | **Tornado Diagram** | Sensitivity analysis â€” which inputs drive uncertainty |
    | **Heatmap** | Multi-attribute comparison across alternatives |
    | **Radar Chart** | Stakeholder profile comparison across criteria |

    ðŸ“– *Review: [Module 5](05-visualization-tools.md)*

### Module 6: Case Studies

??? question "What method was used in each case study?"

    | Case Study | Product Type | Method |
    |------------|--------------|--------|
    | **NEXCOAG** | Anticoagulant | DOOR (composite: bleeding events) |
    | **NEXONC** | Oncology immunotherapy | MCDA (stakeholder preferences) |
    | **NEXVAX** | Vaccine | SBRF (population-level assessment) |

    ðŸ“– *Review: [Module 6](06-case-studies.md)*

### Module 8: Regulatory Reference

??? question "What are the key differences between FDA and EMA B-R frameworks?"

    | Aspect | FDA | EMA |
    |--------|-----|-----|
    | **Framework** | 5 Dimensions (PDUFA) | PrOACT-URL |
    | **Effects Table** | Encouraged | Required |
    | **RMP** | REMS (selective) | Mandatory for all |
    | **Patient Input** | PFDD programs | PRIME consultation |

    ðŸ“– *Review: [Module 8](08-regulatory-reference.md)*

---

## Part 4: Scenario-Based Quiz

Test your understanding with these scenario-based questions:

### Question 1: Framework Application

!!! question "Scenario"

    A sponsor is developing an effects table for a new diabetes drug. They have efficacy data at Week 24 and Week 52, but safety data only through Week 24.

    **What is the most appropriate approach?**

    A. Use Week 52 for efficacy and Week 24 for safety, noting the different timepoints
    B. Use only Week 24 data for both to maintain consistency
    C. Extrapolate safety data to Week 52 using modeling
    D. Present two separate effects tables for different timepoints

<details>
<summary>Click for answer and explanation</summary>

**Answer: A or D (both acceptable, A preferred)**

**Explanation:** Transparency is key. Option A is pragmaticâ€”use the best available data while clearly documenting the different timepoints. Option D provides maximum transparency but may be cumbersome. Option B discards valuable efficacy data. Option C introduces modeling assumptions that may not be justified.

**Key principle:** Always document limitations and timepoint differences in effects tables.
</details>

---

### Question 2: Method Selection

!!! question "Scenario"

    You're assessing a vaccine with these characteristics:
    - Primary endpoint is a composite (infection + hospitalization + death)
    - Patient values are relatively uniform (everyone wants to avoid disease)
    - Regulatory submission requires quantitative B-R

    **Which method is most appropriate?**

    A. MCDA with equal weights
    B. DOOR analysis
    C. Effects table only
    D. Qualitative narrative

<details>
<summary>Click for answer and explanation</summary>

**Answer: B (DOOR analysis)**

**Explanation:** DOOR is ideal when:
- There's a composite endpoint with natural hierarchy (death > hospitalization > infection)
- Stakeholder values are relatively aligned (don't need MCDA's explicit weighting)
- You want to avoid arbitrary numerical weights

MCDA would add complexity without much benefit since values are uniform. Effects table alone doesn't leverage the hierarchy. Qualitative narrative doesn't meet the quantitative requirement.
</details>

---

### Question 3: Communication

!!! question "Scenario"

    Your B-R analysis shows NNT = 15 for the primary efficacy endpoint and NNH = 200 for a serious adverse event.

    **Which statement best communicates this to a patient advisory board?**

    A. "The relative benefit exceeds the relative risk by a factor of 13"
    B. "For every 15 people treated, 1 additional person benefits; for every 200 treated, 1 experiences a serious side effect"
    C. "The NNT/NNH ratio of 0.075 indicates favorable benefit-risk"
    D. "Efficacy is statistically significant with p<0.001"

<details>
<summary>Click for answer and explanation</summary>

**Answer: B**

**Explanation:** Patient audiences understand concrete numbers better than ratios or statistical jargon. Option B translates NNT/NNH into relatable termsâ€”"for every X people..."

Option A is technically correct but abstract. Option C uses jargon patients won't understand. Option D addresses statistical significance, not clinical meaningfulness.

**Key principle:** Translate statistics into patient-friendly language without losing accuracy.
</details>

---

### Question 4: Risk Management

!!! question "Scenario"

    A new biologic has a serious but rare risk of progressive multifocal leukoencephalopathy (PML) in immunocompromised patients. The risk appears to be higher in patients who previously received certain immunosuppressants.

    **What RMM approach is most appropriate?**

    A. Add warning to label only (routine RMM)
    B. Contraindication for all immunosuppressed patients
    C. Targeted RMM: screening checklist, HCP guide, patient alert card
    D. Restricted distribution with prescriber certification (REMS)

<details>
<summary>Click for answer and explanation</summary>

**Answer: C (Targeted RMM)**

**Explanation:** The risk is serious but predictable (associated with specific prior treatments). A targeted RMM enables:
- Screening checklist to identify high-risk patients
- HCP education on monitoring
- Patient awareness of symptoms

Option A (label only) is insufficient for a serious risk. Option B (blanket contraindication) may be overly restrictive since not all immunocompromised patients are at high risk. Option D (REMS) may be excessive if targeted measures can adequately mitigate risk.

**Key principle:** RMMs should be proportionate to the risk and targeted to those who can act on the information.
</details>

---

## Part 5: Scoring & Interpretation

### Calculate Your Scores

**Knowledge Score:** Sum your ratings (1-5) for all knowledge questions, then divide by the number of questions.

| Domain | Your Total | Max Possible | Your Average |
|--------|------------|--------------|--------------|
| Framework & Methodology | ___ | 25 | ___/5 = ___ |
| Quantitative Methods | ___ | 30 | ___/6 = ___ |
| Visualization & Communication | ___ | 25 | ___/5 = ___ |
| Stakeholder Integration | ___ | 25 | ___/5 = ___ |
| Risk Management | ___ | 25 | ___/5 = ___ |
| **Overall Knowledge** | ___ | 130 | ___/26 = ___ |

**Quiz Score:** ___/4 correct

### Interpretation Guide

| Average Score | Level | Description |
|---------------|-------|-------------|
| 1.0 - 1.9 | **Novice** | Limited exposure; foundational learning needed |
| 2.0 - 2.9 | **Developing** | Some knowledge; requires structured development |
| 3.0 - 3.9 | **Competent** | Working knowledge; can apply with guidance |
| 4.0 - 4.4 | **Proficient** | Strong capabilities; works independently |
| 4.5 - 5.0 | **Expert** | Deep expertise; can mentor others |

---

## Part 6: Development Planning

### Identify Priority Areas

Based on your assessment, list your top 3 development priorities:

| Priority | Domain/Topic | Current Level | Target Level | Timeline |
|----------|--------------|---------------|--------------|----------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |

### Recommended Development Activities

| Development Need | Recommended Actions |
|------------------|---------------------|
| Framework knowledge | Complete Modules 1-2; read CIOMS WG XII report |
| Quantitative methods | Complete DOOR/MCDA tutorials; practice with examples |
| Visualization | Complete Module 5; create visualizations for your products |
| Stakeholder integration | Observe patient advisory boards; join preference study |
| Risk management | Shadow RMM design project; review REMS examples |

### Track Your Progress

!!! tip "Retake Assessment"

    Revisit this assessment in 6 months to measure your development:

    - **Date of initial assessment:** ____________
    - **Date of follow-up:** ____________
    - **Key accomplishments:** ____________

---

## Competency Framework Alignment

This assessment aligns with the following professional competencies:

| Competency Area | Related Toolkit Modules |
|-----------------|------------------------|
| Regulatory Science | Modules 1, 8 |
| Data Analysis | Modules 3, 5 |
| Communication | Modules 4, 5, 6 |
| Risk Management | Modules 3, 4 |
| Strategic Thinking | Modules 1, 2, 6 |

---

## Certificate of Completion

!!! success "Congratulations!"

    By completing all seven modules, you have demonstrated commitment to benefit-risk excellence.

    **Next steps:**
    - Review Module 8: Regulatory Reference for regional requirements
    - Apply your learning to a real product assessment
    - Share your knowledge with colleagues

    Visit **[nexvigilant.com](https://www.nexvigilant.com)** for advanced capability development programs.

---

## Further Resources

| Resource | Description |
|----------|-------------|
| [Module 8: Regulatory Reference](08-regulatory-reference.md) | Regional requirements |
| [CIOMS WG XII Reference](../reference/cioms-wg-xii.md) | Source framework |
| [Glossary](../reference/glossary.md) | Term definitions |
| [Home](../index.md) | Toolkit overview |

---

## Key Takeaways

!!! success "Essential Points"

    1. **Self-assessment is the first step** to identifying competency gaps and development priorities
    2. **B-R capability spans five domains** â€” framework knowledge, quantitative methods, visualization, stakeholder integration, and risk management
    3. **Competency develops progressively** from novice to expert through structured practice and application
    4. **Regular re-assessment** (every 6 months) helps track professional growth and identify new development needs
    5. **Practical application** is essential â€” knowledge alone is not sufficient without hands-on experience

---

!!! warning "Educational Disclaimer"

    This module is provided for **educational purposes only**. It should NOT be used for regulatory submissions or personnel certifications without validation by qualified professionals.

---

[Continue to Module 8: Regulatory Reference â†’](08-regulatory-reference.md){ .md-button .md-button--primary }
[Return to Home](../index.md){ .md-button }

---

**NexVigilant** | *Empowerment Through Vigilance*
